Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effect of Experimental Ischemic Stroke and PGE(2) EP1 Selective Antagonism in Alzheimer's Disease Mouse Models

Full text
Author(s):
Mendes, Fulvio R. [1, 2] ; Leclerc, Jenna L. [2, 3, 4, 5] ; Liu, Lei [2] ; Kamat, Pradip K. [2] ; Naziripour, Arash [2] ; Hernandez, Damian [2] ; Li, Chris [2] ; Ahmad, Abdullah S. [2] ; Dore, Sylvain [2, 3, 4]
Total Authors: 9
Affiliation:
[1] Univ Fed ABC, Ctr Ciencias Nat & Humanas, Sao Bernardo Do Campo - Brazil
[2] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL - USA
[3] Univ Florida, Coll Med, Dept Neurosci, Neurol, Psychiat, Gainesville, FL 32610 - USA
[4] Univ Florida, Coll Med, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL - USA
[5] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 - USA
Total Affiliations: 5
Document type: Journal article
Source: JOURNAL OF ALZHEIMER'S DISEASE; v. 74, n. 1, p. 173-187, 2020.
Web of Science Citations: 0
Abstract

Background: Neuroinflammation has been recognized as an important factor in the pathogenesis of Alzheimer's disease (AD). One of the most recognized pathways in mediating neuroinflammation is the prostaglandin E-2-EP1 receptor pathway. Objective: Here, we examined the efficacy of the selective EP1 antagonist ONO-8713 in limiting amyloid-beta (A beta), lesion volumes, and behavioral indexes in AD mouse models after ischemic stroke. Methods: Transgenic APP/PS1, 3xTgAD, and wildtype (WT) mice were subjected to permanent distal middle cerebral artery occlusion (pdMCAO) and sham surgeries. Functional outcomes, memory, anatomical outcomes, and A beta concentrations were assessed 14 days after surgery. Results: pdMCAO resulted in significant deterioration in functional and anatomical outcomes in the transgenic mice compared with the WT mice. No relevant differences were observed in the behavioral tests when comparing the ONO-8713 and vehicle-treated groups. Significantly lower cavitation (p = 0 .0373) and percent tissue loss (p = 0.0247) were observed in APP/PS1 + ONO-8713 mice compared with the WT + ONO-8713 mice. However, the percent tissue injury was significantly higher in APP/PS1 + ONO-8713 mice compared with the WT + ONO-8713 group (p = 0.0373). Percent tissue loss was also significantly lower in the 3xTgAD + ONO-8713 mice than in the WT + ONO-8713 mice (p = 0.0185). ONO-8713 treatment also attenuated cortical microgliosis in APP/PS1 mice as compared with the vehicle (p = 0.0079); however, no differences were observed in astrogliosis across the groups. Finally, APP/PS1 mice presented with characteristic A beta load in the cortex while 3xTgAD mice exhibited very low A beta levels. Conclusion: In conclusion, under the experimental conditions, EP1 receptor antagonist ONO-8713 showed modest benefits in anatomical outcomes after stroke, mainly in APP/PS1 mice. (AU)

FAPESP's process: 14/18702-4 - Better understanding the neuroprotective mechanisms of Korean ginseng in stroke
Grantee:Fulvio Rieli Mendes
Support Opportunities: Scholarships abroad - Research